CoChat

Genetic Association with Response to Intravitreal Ranibizumab in Patients with Neovascular AMD

Open access
Kloeckener-Gruissem, Barbara, Barthelmes, Daniel, Labs, Stephan, Schindler, Christian, Kurz-Levin, Malaika, Michels, Stephan, Fleischhauer, Johannes, Berger, Wolfgang, Sutter, Florian, Menghini, Moreno · 2011 · Investigative Opthalmology & Visual Science

The DOI matches its Crossref record; 57 of the 57 references it cites were found in a registry or an index.

Abstract

PURPOSE: Neovascular age-related macular degeneration (AMD) resulting in decreased central vision severely impairs affected individuals. Current standard treatment is an intravitreal anti-VEGF therapy (ranibizumab), but responses to treatment show large variability. Genetic factors that influence AMD and that affect the outcome of ranibizumab treatment were sought within a sample of Swiss patients. METHODS: Changes in visual acuity (VA) after initiation of anti-VEGF treatment were observed during 12 months, and percentiles of VA were calculated. Genotypes of polymorphisms in known AMD susceptibility loci (CFH, CFB, HTRA1, AMRS2, and VEGFA) as well as not yet reported AMD-associated genes (KDR, LRP5, and FZD4) were determined, and their frequencies were compared. RESULTS: Of the 309 eyes included in the study, 243 completed VA assessment. On average, 3.9 ±2.6 ranibizumab injections were administered. Based on the change in visual acuity, two responder groups were established: 63 eyes were assigned to the poor responders (≤25th percentile) and 63 eyes to the good responders (≥75th percentile). Individuals with genotype CC of p.Y402H in CFH had a decreased chance of positive treatment outcome compared with those with the CT and TT genotypes (P = 0.005 and P = 0.006). In this study, the genotype combination of AG at CFH with CT at FZD4 (SNP rs10898563) promised an increased chance of positive treatment outcome (P = 0.004). Furthermore, the association with the known genetic susceptibility loci CFH, HTRA1, and AMRS2 were confirmed, and a risk-conferring polymorphism in one new locus, LRP5, was identified. CONCLUSIONS: Genetic predisposition may account for the variability in response to anti-VEGF treatment.

Overview

Integrity signals

Registry

Crossref · 10.1167/iovs.10-6080

Cites

57 of 57 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Cited by

See all 120

Metadata

Authors
Kloeckener-Gruissem, B., Barthelmes, D., Labs, S., Schindler, C., Kurz-Levin, M., Michels, S., Fleischhauer, J., Berger, W., Sutter, F., & Menghini, M.
Affiliations
  • From the Institute of Medical Molecular Genetics, University of Zurich, Schwerzenbach, Switzerland; the 2Department of Biology, ETHZ (Eidgenössische Technische Hochschule Zürich), Zurich, Switzerland;
  • The University of Sydney (AU)
  • University of Zurich (CH)
  • Swiss Tropical and Public Health Institute (CH)
  • University Hospital Zurich (CH)
  • Triemli Hospital (CH)
Corresponding author
  • Barthelmes, Daniel
  • Labs, Stephan
  • Schindler, Christian
  • Kurz-Levin, Malaika
  • Michels, Stephan
  • Fleischhauer, Johannes
  • Berger, Wolfgang
  • Sutter, Florian
  • Menghini, Moreno
Venue
Investigative Opthalmology & Visual Science
Published
2011-06-30
Volume
52
Issue
7
Pages
4694
ISSN
  • 0146-0404 (ISSN-L)
  • 1552-5783
OpenAlex
W2018291910
Cited by
120
References
57
Citations by year
2026: 3 · 2025: 1 · 2024: 2 · 2022: 5 · 2021: 4 · 2020: 3 · 2019: 7 · 2018: 9 · 2017: 8 · 2016: 7 · 2015: 14 · 2014: 16 · 2013: 21 · 2012: 18
FWCI
17.10
Type
journal article
Language
en
Open access
Locations
  • Investigative Ophthalmology & Visual Science (publishedVersion, public-domain)
  • PubMed (publishedVersion)
  • Zurich Open Repository and Archive (University of Zurich) (acceptedVersion)
  • Zurich Open Repository and Archive (University of Zurich) (submittedVersion)
  • Zurich Open Repository and Archive (University of Zurich)
Topics
  • Health Sciences › Medicine › Ophthalmology › Retinal Diseases and Treatments
  • Health Sciences › Medicine › Ophthalmology › Ocular Diseases and Behçet’s Syndrome
  • Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Retinal Imaging and Analysis
Keywords
neovascular age-related macular degeneration, ranibizumab, anti-VEGF therapy, treatment response variability, genetic susceptibility, complement factor H, CFH Y402H polymorphism, FZD4, LRP5, HTRA1, VEGF-A, KDR, visual acuity, genetic association
MeSH terms
Ranibizumab, High-Temperature Requirement A Serine Peptidase 1, Aged, Aged, 80 and over, Antibodies, Monoclonal, DNA, Dose-Response Relationship, Drug, Female, Fluorescein Angiography, Follow-Up Studies, Fundus Oculi, Genotype, Humans, Macular Degeneration, Male, Polymorphism, Genetic, Complement Factor B, Proteins, Serine Endopeptidases, Time Factors, Visual Acuity, Retinal Neovascularization, Polymerase Chain Reaction, Complement Factor H, Genetic Predisposition to Disease, Tomography, Optical Coherence, Vascular Endothelial Growth Factor A, Intravitreal Injections, Antibodies, Monoclonal, Humanized

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.